Golubicić Ivana, Bokun Jelena, Nikitović Marina, Mladenović Jasmina, Sarić Milan, Bekić Zoran
Institute of Oncology and Radiology of Serbia, Pasterova 14, 11000 Beograd.
Srp Arh Celok Lek. 2003 May-Jun;131(5-6):226-31. doi: 10.2298/sarh0306226g.
The aim of this study was: 1. to evaluate treatment results of combined therapy (surgery, postoperative craniospinal radiotherapy with or without chemotherapy) and 2. to assess factors affecting prognosis (extend of tumor removal, involvement of the brain stem, extent of disease, postoperative meningitis, shunt placement, age, sex and time interval from surgery to start of postoperative radiotherapy).
During the period 1986-1996, 78 patients with medulloblastoma, aged 1-22 years (median 8.6 years), were treated with combined modality therapy and 72 of them were evaluable for the study endpoints. Entry criteria were histologically proven diagnosis, age under 22 years, and no history of previous malignant disease. The main characteristics of the group are shown in Table 1. Twenty-nine patients (37.2%) have total, 8 (10.3%) near total and 41 (52.5%) partial removal. Seventy-two of 78 patients were treated with curative intent and received postoperative craniospinal irradiation. Radiotherapy started 13-285 days after surgery (median 36 days). Only 13 patients started radiotherapy after 60 days following surgery. Adjuvant chemotherapy was applied in 63 (80.7%) patients. The majority of them (46; 73%) received chemotherapy with CCNU and Vincristine. The survival rates were calculated with the Kaplan-Meier method and the differences in survival were analyzed using the Wilcoxon test and log-rank test.
The follow-up period ranged from 1-12 years (median 3 years). Five-year overall survival (OS) was 51% and disease-free survival (DFS) 47% (Graph 1). During follow-up 32 relapses occurred. Patients having no brain stem infiltration had significantly better survival (p = 0.0023) (Graph 2). Patients with positive myelographic findings had significantly poorer survival compared to dose with negative myelographic findings (p = 0.0116). Significantly poorer survival was found in patients with meningitis developing in the postoperative period, with no patient living longer than two years (p = 0.0134) (Graph 3). By analysis of OS and DFS in relation to presence of the malignant cells in liquor, statistically significant difference, i.e. positive CSF cytology was not obtained, which was of statistical importance for survival (p = 0.8207). Neither shunt placement nor shunt type showed any impact on survival (p = 0.5307 and 0.7119, respectively). Children younger than three years had significantly poorer survival compared to those older than 16 years (p = 0.0473). Although there was a better survival rate in females than in males this was not statistically significant (p = 0.2386). The analysis results of treatment showed that significantly better survival occurred in patients in whom total or subtotal tumor removal was possible (p = 0.0022) (Graph 4). Patients who started radiotherapy within two months after surgery have better survival, but again this was not statistically significant, probably due to the small number of patients receiving delayed radiotherapy (p = 0.2231) (Graph 5).
Based on this factors standard and high risk group could be defined. Combined chemotherapy should to be investigated particularly for high risk subgroup. Future research should be done to define new therapeutic modalities (gene therapy, compounds active in tumor antiangiogenesis etc).
本研究的目的是:1. 评估综合治疗(手术、术后全脑全脊髓放疗,联合或不联合化疗)的治疗效果;2. 评估影响预后的因素(肿瘤切除范围、脑干受累情况、疾病范围、术后脑膜炎、分流管置入、年龄、性别以及手术至术后放疗开始的时间间隔)。
在1986年至1996年期间,78例年龄在1至22岁(中位年龄8.6岁)的髓母细胞瘤患者接受了综合治疗,其中72例可用于研究终点评估。纳入标准为组织学确诊、年龄在22岁以下且无既往恶性疾病史。该组患者的主要特征见表1。29例患者(37.2%)肿瘤完全切除,8例(10.3%)接近完全切除,41例(52.5%)部分切除。78例患者中有72例接受了根治性治疗并接受了术后全脑全脊髓照射。放疗在术后13至285天开始(中位时间36天)。只有13例患者在术后60天后开始放疗。63例(80.7%)患者接受了辅助化疗。其中大多数患者(46例;73%)接受了CCNU和长春新碱化疗。采用Kaplan-Meier法计算生存率,并使用Wilcoxon检验和对数秩检验分析生存差异。
随访期为1至12年(中位时间3年)。5年总生存率(OS)为51%,无病生存率(DFS)为47%(图1)。随访期间发生了32例复发。无脑干浸润的患者生存率显著更高(p = 0.0023)(图2)。脊髓造影结果阳性的患者与脊髓造影结果阴性的患者相比,生存率显著更低(p = 0.0116)。术后发生脑膜炎的患者生存率显著更低,无一例患者存活超过两年(p = 0.0134)(图3)。通过分析OS和DFS与脑脊液中恶性细胞的关系,未获得统计学显著差异,即脑脊液细胞学阳性对生存无统计学意义(p = 0.8207)。分流管置入和分流管类型对生存均无影响(分别为p = 0.5307和0.7119)。3岁以下儿童的生存率显著低于16岁以上儿童(p = 0.0473)。尽管女性生存率高于男性,但差异无统计学意义(p = 0.2386)。治疗分析结果表明,肿瘤能够完全或次全切除的患者生存率显著更高(p = 0.0022)(图4)。术后两个月内开始放疗的患者生存率更高,但同样差异无统计学意义,可能是因为接受延迟放疗的患者数量较少(p = 0.2231)(图5)。
基于这些因素,可以定义标准风险组和高风险组。应特别针对高风险亚组研究联合化疗。未来的研究应致力于确定新的治疗模式(基因治疗、肿瘤抗血管生成活性化合物等)。